https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3AAnti-obesity_medication%2F21%2Fen
Translations:Anti-obesity medication/21/en - Revision history
2026-07-13T08:09:37Z
Revision history for this page on the wiki
MediaWiki 1.43.0
https://wiki.tiffa.net/w/index.php?title=Translations:Anti-obesity_medication/21/en&diff=125277&oldid=prev
FuzzyBot: Importing a new version from external source
2024-03-07T09:16:04Z
<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>{| class="wikitable"<br />
|+<br />
!Medication Name<br />
!Trade name(s)<br />
!Mechanism of action<br />
!Current FDA Status<br />
!placebo-adjusted percent bodyweight lost (highest dose studied)<br />
|-<br />
|[[Retatrutide]]<br />
|<br />
|GLP-1, [[GIP receptor|GIP]], and [[glucagon receptor]] triple agonist<br />
|In clinical trials<br />
|24 percent in a Phase II trial<br />
|-<br />
|[[Exenatide]]<br />
|Byetta<br />
|[[GLP-1 receptor agonist]]<br />
|Approved for type 2 diabetes<br />
|{{convert|2.5|kg}}<br />
|-<br />
|[[Cetilistat]]<br />
|<br />
|Absorption inhibitor<br />
|Not approved<br />
| {{convert|1.5|kg}}<br />
|-<br />
| [[Tesofensine]] (NS2330)<br />
|<br />
|[[Serotonin–norepinephrine–dopamine reuptake inhibitor]]<br />
|Not FDA approved<br />
|10.6 percent</div>
FuzzyBot